The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients
Open accessAbstract
Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector T cells (Teffs) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression has long been the only therapeutic option, activating/expanding Tregs may achieve the same objective without the toxicity of immunosuppression. We showed that low-dose interleukin-2 (ld-IL-2) safely expands/activates Tregs in patients with AID, such HCV-induced vasculitis and Type 1 Diabetes (T1D). Here we analyzed the kinetics and dose-relationship of IL-2 effects on immune responses in T1D patients. Ld-IL-2 therapy induced a dose-dependent increase in CD4+Foxp3+ and CD8+Foxp3+ Treg numbers and proportions, the duration of which was markedly dose-dependent. Tregs expressed enhanced levels of activation markers, including CD25, GITR, CTLA-4 and basal pSTAT5, and retained a 20-fold higher sensitivity to IL-2 than Teff and NK cells. Plasma levels of regulatory cytokines were increased in a dose-dependent manner, while cytokines linked to Teff and Th17 inflammatory cells were mostly unchanged. Global transcriptome analyses showed a dose-dependent decrease in immune response signatures. At the highest dose, Teff responses against beta-cell antigens were suppressed in all 4 patients tested. These results inform of broader changes induced by ld-IL-2 beyond direct effects on Tregs, and relevant for further development of ld-IL-2 for therapy and prevention of T1D, and other autoimmune and inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., & Ochs, H. D. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,402
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,636
Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
Morgan, D. A., Ruscetti, F. W., & Gallo, R. (1976) · Science · doi:10.1126/science.181845 · Cited by 2,493
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes
Finland, G. O. T. 1. D. I., Todd, J. A., the Wellcome Trust Case Control Consortium, Walker, N. M., Cooper, J. D., Smyth, D. J., Downes, K., Plagnol, V., Bailey, R., Nejentsev, S., et al. (2007) · Nature Genetics · doi:10.1038/ng2068 · Cited by 1,456
Regulatory T cells in transplantation tolerance
Wood, K. J., & Sakaguchi, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri1027 · Cited by 1,317
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265
Genome-wide association studies: theoretical and practical concerns
Wang, W. Y. S., Barratt, B. J., Clayton, D. G., & Todd, J. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1522 · Cited by 1,165
Foxp3-dependent programme of regulatory T-cell differentiation
Gavin, M. A., Rasmussen, J. P., Fontenot, J. D., Vasta, V., Manganiello, V. C., Beavo, J. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05543 · Cited by 1,135
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
Koreth, J., Matsuoka, K.-I., Kim, H. T., McDonough, S. M., Bindra, B., Alyea, E. P., Armand, P., Cutler, C., Ho, V. T., Treister, N. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108188 · Cited by 1,119
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
Wing, K., & Sakaguchi, S. (2010) · Nature Immunology · doi:10.1038/ni.1818 · Cited by 1,107
Natural regulatory T cells control the development of atherosclerosis in mice
Ait-Oufella, H., Salomon, B. L., Potteaux, S., Robertson, A.-K. L., Gourdy, P., Zoll, J., Merval, R., Esposito, B., Cohen, J. L., Fisson, S., et al. (2006) · Nature Medicine · doi:10.1038/nm1343 · Cited by 1,100
Self-citationC9orf72 nucleotide repeat structures initiate molecular cascades of disease
Haeusler, A. R., Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M.-S., Maragakis, N. J., Troncoso, J. C., Pandey, A., Sattler, R., et al. (2014) · Nature · doi:10.1038/nature13124 · Cited by 978
Defective Suppressor Function in CD4+CD25+ T-Cells From Patients With Type 1 Diabetes
Lindley, S., Dayan, C. M., Bishop, A., Roep, B. O., Peakman, M., & Tree, T. I. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.92 · Cited by 861
Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
Malek, T. R., & Castro, I. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.004 · Cited by 851
Self-citationMechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases
Buckner, J. H. (2010) · Nature Reviews Immunology · doi:10.1038/nri2889 · Cited by 789
Self-citationPhenotypical and functional specialization of FOXP3+ regulatory T cells
Campbell, D. J., & Koch, M. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri2916 · Cited by 773
Li, S., Rouphael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt, D. S., Johnson, S. E., Milton, A., Rajam, G., et al. (2014) · Nature Immunology · doi:10.1038/ni.2789 · Cited by 770
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, F., Thibault, V., Sene, D., Cacoub, P., & Klatzmann, D. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105143 · Cited by 762
Self-citationZorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 740
Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction
Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A., Salomon, B. L., & Bluestone, J. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.016 · Cited by 729
Innate lymphoid cells — how did we miss them?
Walker, J. A., Barlow, J. L., & McKenzie, A. N. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3349 · Cited by 669
Extrahepatic manifestations of chronic hepatitis C
Cacoub, P., Poynard, T., Ghillani, P., Charlotte, F., Olivi, M., Charles Piette, J., Opolon, P., & for the MULTIVIRC GROUP (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199910)42:10<2204::aid-anr24>3.0.co;2-d · Cited by 648
Oldenhove, G., Bouladoux, N., Wohlfert, E. A., Hall, J. A., Chou, D., Dos santos, L., O'Brien, S., Blank, R., Lamb, E., Natarajan, S., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.10.001 · Cited by 575
Todd, J. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.001 · Cited by 560
Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset
Stiller, C. R., Dupré, J., Gent, M., Jenner, M. R., Keown, P. A., Laupacis, A., Martell, R., Rodger, N. W., von Graffenried, B., & Wolfe, B. M. J. (1984) · Science · doi:10.1126/science.6367043 · Cited by 556
Defective regulatory and effector T cell functions in patients with FOXP3 mutations
Bacchetta, R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25112 · Cited by 511
Matsuoka, K.-I., Koreth, J., Kim, H. T., Bascug, G., McDonough, S., Kawano, Y., Murase, K., Cutler, C., Ho, V. T., Alyea, E. P., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005265 · Cited by 468
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448 · cited 1×
“provided proof of principle that newly-diagnosed T1D could be treated with immunotherapy [31-33].”
Grinberg-Bleyer, Y., Baeyens, A., You, S., Elhage, R., Fourcade, G., Gregoire, S., Cagnard, N., Carpentier, W., Tang, Q., Bluestone, J., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100209 · Cited by 433
Self-citationHartemann, A., Bensimon, G., Payan, C. A., Jacqueminet, S., Bourron, O., Nicolas, N., Fonfrede, M., Rosenzwajg, M., Bernard, C., & Klatzmann, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70113-x · Cited by 428
Self-citationSadlack, B., Löhler, J., Schorle, H., Klebb, G., Haber, H., Sickel, E., Noelle, R. J., & Horak, I. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251111 · Cited by 423
Herold, K. C., Gitelman, S. E., Ehlers, M. R., Gottlieb, P. A., Greenbaum, C. J., Hagopian, W., Boyle, K. D., Keyes-Elstein, L., Aggarwal, S., Phippard, D., et al. (2013) · Diabetes · doi:10.2337/db13-0345 · Cited by 411
Functional Defects and the Influence of Age on the Frequency of CD4+CD25+ T-Cells in Type 1 Diabetes
Brusko, T. M., Wasserfall, C. H., Clare-Salzler, M. J., Schatz, D. A., & Atkinson, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1407 · Cited by 398
Vella, A., Cooper, J. D., Lowe, C. E., Walker, N., Nutland, S., Widmer, B., Jones, R., Ring, S. M., McArdle, W., Pembrey, M. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429843 · Cited by 352
Factors Associated with Early Remission of Type I Diabetes in Children Treated with Cyclosporine
Bougneres, P. F., Carel, J. C., Castano, L., Boitard, C., Gardin, J. P., Landais, P., Hors, J., Mihatsch, M. J., Paillard, M., Chaussain, J. L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198803173181103 · Cited by 330
Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. (2012) · Diabetes · doi:10.2337/db12-0049 · Cited by 314
Self-citationCD4+FOXP3+ T Regulatory Cells in Human Autoimmunity: More Than a Numbers Game
Long, S. A., & Buckner, J. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003224 · Cited by 294
Self-citationLong, S. A., Cerosaletti, K., Bollyky, P. L., Tatum, M., Shilling, H., Zhang, S., Zhang, Z.-Y., Pihoker, C., Sanda, S., Greenbaum, C., et al. (2010) · Diabetes · doi:10.2337/db09-0694 · Cited by 283
Self-citationDendrou, C. A., Plagnol, V., Fung, E., Yang, J. H. M., Downes, K., Cooper, J. D., Nutland, S., Coleman, G., Himsworth, M., Hardy, M., et al. (2009) · Nature Genetics · doi:10.1038/ng.434 · Cited by 274
Identification of CD8 + CD25 + Foxp3 + suppressive T cells in colorectal cancer tissue
Chaput, N., Louafi, S., Bardier, A., Charlotte, F., Vaillant, J.-C., Ménégaux, F., Rosenzwajg, M., Lemoine, F., Klatzmann, D., & Taieb, J. (2009) · Gut · doi:10.1136/gut.2008.158824 · Cited by 264
Self-citationFerraro, A., Socci, C., Stabilini, A., Valle, A., Monti, P., Piemonti, L., Nano, R., Olek, S., Maffi, P., Scavini, M., et al. (2011) · Diabetes · doi:10.2337/db11-0090 · Cited by 250
Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
Hagopian, W., Ferry, R. J., Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Daifotis, A. G., Herold, K. C., et al. (2013) · Diabetes · doi:10.2337/db13-0236 · Cited by 247
Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata
Castela, E., Le Duff, F., Butori, C., Ticchioni, M., Hofman, P., Bahadoran, P., Lacour, J.-P., & Passeron, T. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.504 · Cited by 229
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2014) · Diabetes Care · doi:10.2337/dc13-0604 · Cited by 209
Garg, G., Tyler, J. R., Yang, J. H. M., Cutler, A. J., Downes, K., Pekalski, M., Bell, G. L., Nutland, S., Peakman, M., Todd, J. A., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100272 · Cited by 201
Kennedy-Nasser, A. A., Ku, S., Castillo-Caro, P., Hazrat, Y., Wu, M.-F., Liu, H., Melenhorst, J., Barrett, A. J., Ito, S., Foster, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3205 · Cited by 201
Hori, T., Uchiyama, T., Tsudo, M., Umadome, H., Ohno, H., Fukuhara, S., Kita, K., & Uchino, H. (1987) · Blood · doi:10.1182/blood.v70.4.1069.1069 · Cited by 170
Immune Intervention for Type 1 Diabetes, 2012–2013
Skyler, J. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.1510 · Cited by 159
CD4+Foxp3+ regulatory T cell therapy in transplantation
Tang, Q., Bluestone, J. A., & Kang, S.-M. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr047 · Cited by 159
Ito, S., Bollard, C. M., Carlsten, M., Melenhorst, J. J., Biancotto, A., Wang, E., Chen, J., Kotliarov, Y., Cheung, F., Xie, Z., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.50 · Cited by 117
IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity
Tran, G. T., Hodgkinson, S. J., Carter, N. M., Verma, N. D., Plain, K. M., Boyd, R. A., Robinson, C. M., Nomura, M., Killingsworth, M. C., & Hall, B. M. (2012) · Blood · doi:10.1182/blood-2011-12-396101 · Cited by 99
Toward Further Mapping of the Association Between the IL2RA Locus and Type 1 Diabetes
Qu, H., Montpetit, A., Ge, B., Hudson, T. J., & Polychronakos, C. (2007) · Diabetes · doi:10.2337/db06-1555 · Cited by 98
Orban, T., Beam, C. A., Xu, P., Moore, K., Jiang, Q., Deng, J., Müller, S., Gottlieb, P. A., Spain, L. M., Peakman, M., et al. (2014) · Diabetes · doi:10.2337/db14-0047 · Cited by 96
acDCs enhance human antigen–specific T-cell responses
Martinuzzi, E., Afonso, G., Gagnerault, M. C., Naselli, G., Mittag, D., Combadière, B., Boîtard, C., Chaput, N., Zitvogel, L., Harrison, L. C., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326231 · Cited by 62
Self-citationBattaglia, M., & Roncarolo, M. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.007 · Cited by 51
Low-Dose Antigen Promotes Induction of FOXP3 in Human CD4+ T Cells
Long, S. A., Rieck, M., Tatum, M., Bollyky, P. L., Wu, R. P., Muller, I., Ho, J.-C., Shilling, H. G., & Buckner, J. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003880 · Cited by 49
Self-citationHerold, K., Gitelman, S., Ehlers, Gottlieb, P. A., Greenbaum, C. J., Hagopian, W., Boyle, K., Keyes-Elstein, L., Aggarwal, S., Phippard, D., et al. (2014) · eScholarship (California Digital Library) · Cited by 28
Cited by
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
Klatzmann, D., & Abbas, A. K. (2015) · Nature Reviews Immunology · doi:10.1038/nri3823 · Cited by 636
Self-citationNext-generation regulatory T cell therapy
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A., & Tang, Q. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0041-4 · Cited by 476
Rosenzwajg, M., Lorenzon, R., Cacoub, P., Pham, H. P., Pitoiset, F., El Soufi, K., RIbet, C., Bernard, C., Aractingi, S., Banneville, B., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214229 · Cited by 405
Self-citationvon Spee-Mayer, C., Siegert, E., Abdirama, D., Rose, A., Klaus, A., Alexander, T., Enghard, P., Sawitzki, B., Hiepe, F., Radbruch, A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207776 · Cited by 349
Metadata
- Authors
- Rosenzwajg, M., Churlaud, G., Mallone, R., Six, A., Dérian, N., Chaara, W., Lorenzon, R., Long, S. A., Buckner, J. H., Afonso, G., Pham, H.-P., Hartemann, A., Yu, A., Pugliese, A., Malek, T. R., & Klatzmann, D.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 58
- Pages
- 48-58
- ISSN
- 0896-8411 (ISSN-L)
- OpenAlex
- W2147557220
- Cited by
- 257
- References
- 64
- FWCI
- 11.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.